Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth

BOSTON, May 21 /PRNewswire-FirstCall/ --  Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the appointment of Fred Schiemann to its board of directors as Chief Financial Officer. Mr. Schiemann brings a strong administrative background in the small-cap company sector as well as expertise in taxation, auditing and public securities work.

Mr. Schiemann previously served as the Chief Financial Officer of Xtreme Oil & Gas, Inc. Prior to that, he has held CFO positions in several corporations and currently serves as Treasurer of Biz2Biz.com. Mr. Schiemann's educational background includes an undergraduate degree from the University of Illinois, Chicago Circle Campus as well as an MBA in taxation from Golden Gate University, Sacramento campus. During his years of practice, Mr. Schiemann has been involved with many public registrations and structuring of mergers and acquisitions. His current practice includes an emphasis on administration and consulting to small and micro-cap public companies.

"As we move forward with a strategy for continued growth, it is imperative that we bring a top-level executive on board to assure Solos' financial health," stated Bob Segersten, President of Solos Endoscopy, Inc. "Fred brings the right blend of prior experience, financial expertise and leadership to the position."

The Company recently announced the successful completion of Phase One requirements for the Company's ISO 13485 quality management system (QMS) initiative. The project is divided into four phases, each with predetermined deliverables. Compliance with ISO 13485 is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.